Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging. Belinostat has been granted orphan drug and fast track designation by the FDA, and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014. It is not approved in Europe as of August 2014.The approved pharmaceutical formulation is given intravenously. : 180   Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele. : 179 and 181 


== References ==
This in turn prevents the release of other allergy chemicals and increases the blood supply to the area, providing relief from the typical symptoms of hay fever. Levocetirizine, (R)-(-)-cetirizine, is essentially a chiral switch of (±)-cetirizine. This enantiomer, the eutomer, is more selective and less sedative and the (S)-counterpart, the distomer, is inactive. Chemistry
Chemically, levocetirizine is the active levorotary enantiomer of cetirizine, also called the l-enantiomer of cetirizine. It is a member of the diphenylmethylpiperazine group of antihistamines. History
Levocetirizine was first launched in 2001 by the Belgian pharmaceutical company UCB (Union Chimique Belge). Society and culture
Availability
On 31 January 2017, the Food and Drug Administration approved an over-the-counter preparation. Levocetirizine had previously received authorization by the FDA as a prescription drug in 2007, having already been brought to market throughout much of Europe. In India, a prescription-only drug containing levocetirizine hydrochloride and montelukast is sold as Crohist MK. Brand names
Preparations of levocetirizine are sold under the following brand names:

Xyzal  in Australia, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Hungary, India, Ireland (also Rinozal), Italy, Japan, Lithuania, Netherlands, Poland, Portugal, Romania, Taiwan, Thailand, Turkey, The Philippines, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland and UK. On May 25, 2007, the United States Food and Drug Administration approved Xyzal, where it is co-marketed by Sanofi-Aventis. Zobral in Cyprus
Levobert in India
Xusal in Germany and Mexico
Xozal in Greece
Degraler in Chile
Allevo in Egypt
Zilola, Histisynt, and Xyzal (UCB) in Hungary
Alcet, Curin, and Seasonix in Bangladesh
Vozet and Uvnil in India
T-Day Syrup in Pakistan
Curin in Nepal.